[{"orgOrder":0,"company":"Modus Therapeutics","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Sevuparin Sodium","moa":"Heparanase","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Modus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Modus Therapeutics \/ University of Oxford","highestDevelopmentStatusID":"7","companyTruncated":"Modus Therapeutics \/ University of Oxford"},{"orgOrder":0,"company":"Modus Therapeutics","sponsor":"Ergomed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Sevuparin","moa":"heparin derivatives and low molecular weight (or depolymerized) heparins","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Modus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Modus Therapeutics \/ Ergomed","highestDevelopmentStatusID":"8","companyTruncated":"Modus Therapeutics \/ Ergomed"},{"orgOrder":0,"company":"Modus Therapeutics","sponsor":"Imperial College London","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"Sevuparin","moa":"heparin derivatives and low molecular weight (or depolymerized) heparins","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Modus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Modus Therapeutics \/ Modus Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Modus Therapeutics \/ Modus Therapeutics"},{"orgOrder":0,"company":"Modus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Sevuparin","moa":"heparin derivatives and low molecular weight (or depolymerized) heparins","graph1":"Undisclosed","graph2":"Phase I","graph3":"Modus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Modus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Modus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Modus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sevuparin","moa":"heparin derivatives and low molecular weight (or depolymerized) heparins","graph1":"Nephrology","graph2":"Phase I","graph3":"Modus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Modus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Modus Therapeutics \/ Undisclosed"}]